Nanotech platform combining paclitaxel with siRNA boosts immune response against lung cancer
· Medical Xpressby Steve Benowitz, University of Arizona
edited by Stephanie Baum, reviewed by Andrew Zinin
Stephanie Baum
Scientific Editor
Meet our editorial team
Behind our editorial process
Andrew Zinin
Chief Editor
Meet our editorial team
Behind our editorial process Editors' notes
This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:
fact-checked
peer-reviewed publication
trusted source
proofread
The GIST Add as preferred source
Researchers at the University of Arizona R. Ken Coit College of Pharmacy have developed a new strategy that helps the immune system recognize and attack lung cancer tumors more effectively. By packaging a chemotherapy drug and an RNA molecule in a tiny lipid carrier, the team boosted an immune response that slowed tumor growth and enhanced the effects of immunotherapy.
The findings, published in Nature Communications, describe a nanotechnology-based platform that combines the chemotherapy drug paclitaxel with a gene-silencing molecule known as siRNA. The lipid package improves delivery of both therapies to lung tumor cells.
The approach enhances a process called immunogenic cell death (ICD), a form of cancer cell death that alerts the immune system to the presence of tumors. Researchers increasingly view ICD as a promising way to help the body recognize, attack and remember cancer cells.
Jianqin Lu, John A. and Frances P. Ware Endowed Associate Professor of Pharmaceutical Sciences in the U of A College of Pharmacy and a member of the U of A Comprehensive Cancer Center, led the research.
"Despite the significant potential of ICD-enabled immunotherapy, its therapeutic applications remain underused," Lu said. "Since we know paclitaxel can induce ICD, we improved the delivery of the drug to the tumor by attaching a fatty molecule called a sphingolipid to form a fatty bubble, or nanovesicle. We can deliver more drugs to the tumor site."
As the drug kills cancer cells, a protein called calreticulin (CRT) moves to the surface of dying cells, creating what researchers describe as an "eat me" signal that attracts immune cells. CRT acts as a beacon for cells called phagocytes, which engulf dying tumor cells and help initiate the ICD response.
Some tumors evade this response by using a molecule called STC1, which prevents CRT from reaching the cell surface. As a result, the immune response is weakened and cell-killing T-cell activity is reduced.
To counter that effect, the researchers used a siRNA molecule called siSTC1 to silence STC1 gene activity by co-delivering it with paclitaxel.
The team tested the strategy in two cancer cell lines: Lewis lung cancer cells, which have high STC1 gene expression, and MC38 colon cancer cells, which have lower STC1 expression. The combination of the drug and the siRNA silencing the STC1 gene was much more effective against the lung cancer cells than the MC38 cells.
"If you trigger an ICD immune response, there should be no tumor development or delayed tumor development," Lu said.
Using mouse models of lung cancer, Lu and his colleagues found that the combination of STC1 siRNA and paclitaxel eradicated three out of five tumors and—in some cases—four out of five tumors, depending on the cancer type.
The researchers also found that the siSTC1-paclitaxel package increased tumor sensitivity to PD-1 blockade treatment, a type of cancer immunotherapy that allows the immune system to better recognize and destroy cancer cells.
"You're really changing the tumor microenvironment," Lu said. "The paclitaxel-siSTC1 combination potentiates the PD-1 blockade therapy and the cancer immunotherapy. That's how this kind of process can have an impact."
Lu said the platform could be used to treat many cancer types with high STC1 expression, including non-small cell lung cancer, some colon cancer types, breast cancer, liver cancer and ovarian cancer.
The team hopes to collaborate with clinical oncologists and eventually advance the platform in a phase 1 clinical trial.
Publication details
Wenpan Li et al, Boosting immunogenic tumour cell death via nanotherapeutic targeting of the Stanniocalcin 1 phagocytosis checkpoint for enhanced cancer immunotherapy, Nature Communications (2026). DOI: 10.1038/s41467-026-72526-1
Journal information: Nature Communications
Key medical concepts
Clinical categories
OncologyClinical pharmacology Provided by University of Arizona Who's behind this story?
Stephanie Baum
Master's in TESOL from The New School. Passionate about language learning and editing science news on biology and space exploration. Full profile →
Andrew Zinin
Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →
Citation: Nanotech platform combining paclitaxel with siRNA boosts immune response against lung cancer (2026, June 25) retrieved 26 June 2026 from https://medicalxpress.com/news/2026-06-nanotech-platform-combining-paclitaxel-sirna.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.